SCHEMBL4801356

SCHEMBL4801356

COc1ccc(S(=O)(=O)Nc2ccccc2C(=O)Cl)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.69
HPGD P15428 4/20 0.69
ALDH1A1 P00352 3/20 0.69
L3MBTL1 Q9Y468 3/20 0.69
TP53 P04637 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
HTT P42858 2/20 0.69
KEAP1 Q14145 2/20 0.63
SQSTM1 Q13501 1/20 0.61
NFE2L2 Q16236 1/20 0.61
KCNA5 P22460 1/20 0.60
GAA P10253 5/20 0.58
KMT2A Q03164 2/20 0.58
TUBB4A P04350 1/20 0.57
TUBB P07437 1/20 0.57
TUBA3C P0DPH7 1/20 0.57
TUBA1B P68363 1/20 0.57
TUBA4A P68366 1/20 0.57
TUBB4B P68371 1/20 0.57
TUBB3 Q13509 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30486834 0.87 LMNA (0.70) LMNAHPGDALDH1A1L3MBTL1TP53
SCHEMBL5158052 0.87 LMNA (0.79) LMNAHPGDALDH1A1L3MBTL1TP53
SCHEMBL2477690 0.87 LMNA (0.70) LMNAHPGDALDH1A1L3MBTL1TP53
SCHEMBL2499921 0.84 LMNA (0.67) LMNAHPGDALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL9850093 0.84 KMT2A (0.60) LMNAHPGDALDH1A1SMN1; SMN2HTT
SCHEMBL12768028 0.83 KEAP1 (0.81) LMNAHPGDALDH1A1L3MBTL1TP53
SCHEMBL11010265 0.82 CCR2 (0.61) LMNAALDH1A1KCNA5KMT2AHKDC1
SCHEMBL7213042 0.82 LMNA (0.69) LMNAHPGDALDH1A1L3MBTL1TP53
SCHEMBL4954785 0.81 LMNA (0.62) LMNAHPGDALDH1A1L3MBTL1TP53
SCHEMBL9069174 0.81 ALDH1A1 (0.69) LMNAHPGDALDH1A1L3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385820-B1 ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2011-10-12 EP disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20030187033-A1 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE KCNH1, KCNH2, KCNJ2 LMNA 981/4885HPGD 3102/4885ALDH1A1 1053/4885
US-20030187033-A1 Anthranilamides and methods of their use KCNH1, KCNJ2, KCNH2 LMNA 1186/4885HPGD 3119/4885ALDH1A1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.